Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Powers

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Molecular Cancer Therapeutics|November 12, 2020
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue SarcomaJavier Martín-Broto, Antonio López Pousa, Andrew S Brohl, et al.
Journal for Immunotherapy of Cancer|August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Michael J Wagner, Megan Othus, Sandip P Patel, et al.
Annals of Surgical Oncology|May 8, 2020
The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPECMichael K Turgeon, Adriana C Gamboa, Rachel M Lee, et al.
Annals of Surgical Oncology|October 31, 2022
Conditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC CollaborativeEliza W Beal, Shruthi Srinivas, Chengli Shen, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|February 26, 2021
The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC CollaborativeNadege Fackche, Ryan K Schmocker, Boateng Kubi, et al.
Surgical Oncology|January 19, 2021
A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignanciesJason T Wiseman, Sherif Abdel-Misih, Eliza W Beal, et al.
Annals of Surgical Oncology|October 30, 2019
Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?Jason T Wiseman, Charles Kimbrough, Eliza W Beal, et al.
Cancer|February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trialMichael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|November 21, 2019
Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative StudyTiffany C Lee, Koffi Wima, Jeffrey J Sussman, et al.
Journal of Surgical Oncology|July 7, 2020
Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathwaysOliver S Eng, Andrew M Blakely, Kelly J Lafaro, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Molecular Cancer Therapeutics|November 12, 2020
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue SarcomaJavier Martín-Broto, Antonio López Pousa, Andrew S Brohl, et al.
Journal for Immunotherapy of Cancer|August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Michael J Wagner, Megan Othus, Sandip P Patel, et al.
Annals of Surgical Oncology|May 8, 2020
The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPECMichael K Turgeon, Adriana C Gamboa, Rachel M Lee, et al.
Annals of Surgical Oncology|October 31, 2022
Conditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC CollaborativeEliza W Beal, Shruthi Srinivas, Chengli Shen, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|February 26, 2021
The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC CollaborativeNadege Fackche, Ryan K Schmocker, Boateng Kubi, et al.
Surgical Oncology|January 19, 2021
A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignanciesJason T Wiseman, Sherif Abdel-Misih, Eliza W Beal, et al.
Annals of Surgical Oncology|October 30, 2019
Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?Jason T Wiseman, Charles Kimbrough, Eliza W Beal, et al.
Cancer|February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trialMichael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|November 21, 2019
Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative StudyTiffany C Lee, Koffi Wima, Jeffrey J Sussman, et al.
Journal of Surgical Oncology|July 7, 2020
Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathwaysOliver S Eng, Andrew M Blakely, Kelly J Lafaro, et al.
Pageof 4